tm logo
NEUR-EX
Live/Pending
NON-FINAL ACTION - MAILED

final action

on 11 Dec 2023

Last Applicant/ Owned by

184 Collins Industrial Blvd, Suite A

Athens

GA

30601

Serial Number

97173248 filed on 15th Dec 2021

Registration Number

N/A

Correspondent Address

Devon E. White

WYRICK ROBBINS YATES & PONTON LLP

4101 LAKE BOONE TRAIL, SUITE 300

RALEIGH,NC 27607

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

NEUR-EX

Research and development in the field of neural exosome-based therapeutics for the treatment of neurodegenerative diseases; Research and development in the field of neural exosome-based platforms to harness the inherent properties of neural exosomes for their therapeutic and delivery capabilities; Research and development in the field of neural exosomes to transport a wide range of cargos includinRead More

Classification Information


Class [042]
Computer & Software Services & Scientific Services


Research and development in the field of neural exosome-based therapeutics for the treatment of neurodegenerative diseases; Research and development in the field of neural exosome-based platforms to harness the inherent properties of neural exosomes for their therapeutic and delivery capabilities; Research and development in the field of neural exosomes to transport a wide range of cargos including nucleic acids and proteins to treat a wide range of Central Nervous System (CNS) diseases, inflammatory diseases of the brain, and other auto-immune diseases of the brain caused by destruction of myelin and neuronal injury/death; Research and development in the field of neural exosomes, namely, to engineer exosomes to carry various biologically active drug molecules, target specific cell types or cellular pathways, and enhance the value of existing drug modalities; Research and development in the field of neural exosome platforms to reduce pro-inflammatory t-cells, increase anti-inflammatory t-cells, increase anti-inflammatory macrophages, decrease pro-inflammatory microglia, decrease acute and chronic inflammation, protect axons and neurons, and restore neuronal and myelin integrity for the treatment of Central Nervous System (CNS) diseases, inflammatory diseases of the brain, and other auto-immune diseases of the brain caused by destruction of myelin and neuronal injury/death; Research and development in the field of neural exosome platforms to transport a wide range of cargos including nucleic acids and proteins to treat a wide range of Central Nervous System (CNS) diseases, inflammatory diseases of the brain, and other auto-immune diseases of the brain caused by destruction of myelin and neuronal injury/death; Research and development in the field of next-generation neural exosomes to enhance blood-brain barrier penetration and/or enhance the properties of cell-targeting exosomes

Mark Details


Serial Number

No 97173248

Mark Type

No Service Mark

Attorney Docket Number

No 031928.0010

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
08th Mar 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
08th Mar 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
11th Dec 2023NON-FINAL ACTION WRITTEN
11th Dec 2023NON-FINAL ACTION E-MAILED
11th Dec 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
13th Nov 2023ASSIGNED TO EXAMINER
25th Apr 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
19th Oct 2022SUSPENSION LETTER WRITTEN
19th Oct 2022LETTER OF SUSPENSION E-MAILED
19th Oct 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED